Details of the Drug

General Information of Drug (ID: DMOG2X1)

Drug Name
Trebananib
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [1]
Renal cell carcinoma 2C90 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Drug Type
Recombinant protein
Cross-matching ID
UNII
X8Y5U6NC7E
DrugBank ID
DB12056
TTD ID
D9NL3R
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-1 (ANGPT1) TTWNQ1T ANGP1_HUMAN Inhibitor [4]
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Ovarian cancer
ICD Disease Classification 2C73
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiopoietin-1 (ANGPT1) DTT ANGPT1 1.36E-85 -2.59 -2.11
Angiopoietin-2 (ANGPT2) DTT ANGPT2 3.47E-04 -0.31 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02525536) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
4 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.